patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_443277 | REC_0009401 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 9.4 | 67 | female | 0 | 17 | 6.9 | 1 | alectinib 600 mg BID | 20.1 | true | MSS | 2026-03-15T05:35:59.176754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_816321 | REC_0009402 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 8.1 | 62 | female | 1 | 6 | 3.7 | 1 | entrectinib 600 mg daily | 21.3 | true | MSS | 2026-03-15T05:35:59.177005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650932 | REC_0009403 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 29 | 11.3 | 73 | female | 2 | 14 | 3.8 | 0 | pembrolizumab 200 mg q3w | 36.1 | true | MSS | 2026-03-15T05:35:59.177258+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460273 | REC_0009404 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 8.1 | 77 | female | 1 | 16 | 6.3 | 8 | osimertinib 80 mg daily | 12.1 | true | MSS | 2026-03-15T05:35:59.177503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711955 | REC_0009405 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 7.7 | 67 | male | 1 | 15 | 5.3 | 1 | osimertinib 80 mg daily | 20 | true | MSS | 2026-03-15T05:35:59.177747+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_159964 | REC_0009406 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 8.2 | 62 | male | 0 | 14 | 5.9 | 2 | alectinib 600 mg BID | 16.1 | false | MSS | 2026-03-15T05:35:59.177989+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645852 | REC_0009407 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 25 | 5 | 74 | male | 1 | 17 | 6.9 | 0 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:59.178231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405430 | REC_0009408 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 12.2 | 66 | male | 0 | 9 | 8.8 | 3 | osimertinib 80 mg daily | 7.5 | true | MSI-H | 2026-03-15T05:35:59.178474+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616310 | REC_0009409 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 5.5 | 71 | female | 0 | 60 | 3.8 | 8 | carboplatin + paclitaxel + pembrolizumab | 12.2 | true | MSS | 2026-03-15T05:35:59.178714+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_108868 | REC_0009410 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 7.4 | 64 | male | 1 | 46 | 5.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 17.4 | false | MSS | 2026-03-15T05:35:59.178956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_537314 | REC_0009411 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 11.1 | 79 | female | 1 | 6 | 5.2 | 2 | osimertinib 80 mg daily | 20.8 | false | MSS | 2026-03-15T05:35:59.179202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_809569 | REC_0009412 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 8.6 | 60 | male | 0 | 10 | 4.6 | 1 | entrectinib 600 mg daily | 13 | true | MSS | 2026-03-15T05:35:59.179450+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_822489 | REC_0009413 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 12.2 | 78 | male | 1 | 8 | 4.5 | 5 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.179825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_386962 | REC_0009414 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 7.6 | 81 | female | 1 | 57 | 7.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 8.1 | true | MSS | 2026-03-15T05:35:59.180254+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_710788 | REC_0009415 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 34 | 6.6 | 65 | female | 0 | 19 | 5.8 | 2 | sotorasib 960 mg daily | 16 | false | MSS | 2026-03-15T05:35:59.180548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_135671 | REC_0009416 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 2.9 | 69 | female | 0 | 22 | 5 | 2 | pembrolizumab 200 mg q3w | 27.5 | true | MSS | 2026-03-15T05:35:59.180804+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696219 | REC_0009417 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 8.6 | 65 | male | 0 | 24 | 5.8 | 4 | entrectinib 600 mg daily | 17.5 | false | MSS | 2026-03-15T05:35:59.181053+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_980487 | REC_0009418 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 10.8 | 71 | female | 1 | 18 | 5.5 | 2 | alectinib 600 mg BID | 27.6 | false | MSS | 2026-03-15T05:35:59.181292+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_123143 | REC_0009419 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 23 | 12.5 | 70 | female | 1 | 1 | 6.2 | 0 | alectinib 600 mg BID | 27.5 | false | MSS | 2026-03-15T05:35:59.181529+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430678 | REC_0009420 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 13.4 | 72 | female | 2 | 11 | 6.4 | 7 | sotorasib 960 mg daily | 7.3 | true | MSI-H | 2026-03-15T05:35:59.181761+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744998 | REC_0009421 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 6.5 | 63 | female | 1 | 10 | 4.5 | 1 | sotorasib 960 mg daily | 18 | true | MSS | 2026-03-15T05:35:59.181999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_328207 | REC_0009422 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 9.7 | 69 | female | 1 | 18 | 4.7 | 1 | osimertinib 80 mg daily | 24.1 | true | MSS | 2026-03-15T05:35:59.182240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944279 | REC_0009423 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 15 | 14.2 | 48 | male | 0 | 20 | 5.5 | 4 | entrectinib 600 mg daily | 11.1 | false | MSS | 2026-03-15T05:35:59.182483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_313862 | REC_0009424 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 8.9 | 67 | female | 0 | 17 | 6.2 | 4 | pembrolizumab 200 mg q3w | 6.1 | false | MSS | 2026-03-15T05:35:59.182722+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_269680 | REC_0009425 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 9.1 | 62 | male | 0 | 21 | 6.3 | 1 | alectinib 600 mg BID | 17.6 | true | MSS | 2026-03-15T05:35:59.182966+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_883362 | REC_0009426 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 17.7 | 67 | female | 0 | 0 | 6.8 | 4 | sotorasib 960 mg daily | 9.6 | false | MSS | 2026-03-15T05:35:59.183340+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347878 | REC_0009427 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 5.8 | 73 | male | 1 | 39 | 5.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.3 | true | MSS | 2026-03-15T05:35:59.183599+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_835469 | REC_0009428 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 7.6 | 70 | female | 2 | 5 | 6.4 | 3 | osimertinib 80 mg daily | 6.9 | true | MSS | 2026-03-15T05:35:59.183841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_301833 | REC_0009429 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 7.9 | 70 | female | 2 | 20 | 7.2 | 0 | entrectinib 600 mg daily | 18.9 | true | MSS | 2026-03-15T05:35:59.184124+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_942294 | REC_0009430 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11.8 | 66 | female | 1 | 27 | 5.1 | 5 | alectinib 600 mg BID | 15.6 | true | MSS | 2026-03-15T05:35:59.184390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324046 | REC_0009431 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.7 | 74 | female | 1 | 25 | 7.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.2 | false | MSS | 2026-03-15T05:35:59.184642+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744338 | REC_0009432 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 8.6 | 66 | female | 0 | 13 | 5.9 | 6 | sotorasib 960 mg daily | 13.5 | false | MSS | 2026-03-15T05:35:59.184888+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_949858 | REC_0009433 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 4.7 | 62 | female | 1 | 49 | 6.4 | 9 | carboplatin + paclitaxel + pembrolizumab | 13.3 | true | MSS | 2026-03-15T05:35:59.185133+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_628096 | REC_0009434 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 12.8 | 69 | female | 1 | 14 | 6.5 | 5 | alectinib 600 mg BID | 8 | false | MSI-H | 2026-03-15T05:35:59.185392+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_774360 | REC_0009435 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 11.3 | 55 | female | 1 | 14 | 7.1 | 2 | osimertinib 80 mg daily | 9.2 | true | MSS | 2026-03-15T05:35:59.185632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614541 | REC_0009436 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 12.2 | 77 | female | 2 | 13 | 4 | 5 | alectinib 600 mg BID | 6.9 | false | MSS | 2026-03-15T05:35:59.185867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_212728 | REC_0009437 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 19 | 5.5 | 76 | female | 2 | 23 | 2.1 | 0 | pembrolizumab 200 mg q3w | 36.5 | false | MSS | 2026-03-15T05:35:59.186099+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_284646 | REC_0009438 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 6.4 | 76 | female | 0 | 21 | 4.9 | 6 | entrectinib 600 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:59.186342+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_320152 | REC_0009439 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 10.7 | 77 | female | 1 | 15 | 2.7 | 2 | osimertinib 80 mg daily | 25.2 | false | MSS | 2026-03-15T05:35:59.186698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_866064 | REC_0009440 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 22 | 9.3 | 82 | female | 1 | 25 | 5.7 | 0 | sotorasib 960 mg daily | 26.9 | true | MSS | 2026-03-15T05:35:59.186955+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_374222 | REC_0009441 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 9.1 | 60 | male | 0 | 11 | 5.9 | 4 | sotorasib 960 mg daily | 17.4 | false | MSS | 2026-03-15T05:35:59.187208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_605897 | REC_0009442 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 9 | 64 | female | 0 | 24 | 4.4 | 7 | sotorasib 960 mg daily | 9.2 | true | MSS | 2026-03-15T05:35:59.187447+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_874604 | REC_0009443 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 17.2 | 65 | male | 0 | 16 | 6 | 1 | sotorasib 960 mg daily | 31 | true | MSI-H | 2026-03-15T05:35:59.187686+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_130472 | REC_0009444 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 11.2 | 67 | female | 1 | 14 | 5.6 | 2 | osimertinib 80 mg daily | 14.9 | true | MSS | 2026-03-15T05:35:59.187923+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449348 | REC_0009445 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 9.3 | 60 | female | 1 | 13 | 6 | 2 | osimertinib 80 mg daily | 26.5 | true | MSS | 2026-03-15T05:35:59.188231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417947 | REC_0009446 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 10.4 | 71 | male | 2 | 17 | 3.8 | 8 | alectinib 600 mg BID | 16.3 | false | MSS | 2026-03-15T05:35:59.188500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_367286 | REC_0009447 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 35 | 12.1 | 57 | male | 1 | 10 | 5.4 | 4 | alectinib 600 mg BID | 7.1 | true | MSS | 2026-03-15T05:35:59.188752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_600956 | REC_0009448 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 7.3 | 76 | female | 1 | 17 | 4.5 | 4 | sotorasib 960 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:59.189008+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127507 | REC_0009449 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 26 | 9.1 | 51 | female | 0 | 0 | 4.4 | 0 | sotorasib 960 mg daily | 27.9 | false | MSS | 2026-03-15T05:35:59.189267+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121899 | REC_0009450 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 4.3 | 69 | female | 1 | 26 | 4.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 13.8 | true | MSS | 2026-03-15T05:35:59.189511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_715732 | REC_0009451 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 13.4 | 58 | female | 0 | 22 | 5.5 | 6 | alectinib 600 mg BID | 15.1 | true | MSI-H | 2026-03-15T05:35:59.189771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458804 | REC_0009452 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 15.4 | 63 | female | 0 | 22 | 6.7 | 1 | osimertinib 80 mg daily | 26.4 | false | MSS | 2026-03-15T05:35:59.190140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785764 | REC_0009453 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 13 | 61 | male | 1 | 19 | 4 | 3 | osimertinib 80 mg daily | 15 | true | MSI-H | 2026-03-15T05:35:59.190413+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173088 | REC_0009454 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 15.3 | 63 | male | 1 | 10 | 5 | 7 | osimertinib 80 mg daily | 15.6 | true | MSI-H | 2026-03-15T05:35:59.190719+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778422 | REC_0009455 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 13.8 | 84 | female | 1 | 5 | 5 | 4 | osimertinib 80 mg daily | 20.9 | true | MSS | 2026-03-15T05:35:59.191046+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141967 | REC_0009456 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 11.4 | 72 | female | 0 | 14 | 4.8 | 6 | sotorasib 960 mg daily | 7.5 | true | MSI-H | 2026-03-15T05:35:59.191542+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_241429 | REC_0009457 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 16.2 | 61 | female | 1 | 8 | 5.2 | 9 | osimertinib 80 mg daily | 11.8 | true | MSS | 2026-03-15T05:35:59.192005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233422 | REC_0009458 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 17.3 | 71 | female | 1 | 9 | 6 | 9 | sotorasib 960 mg daily | 18.2 | false | MSS | 2026-03-15T05:35:59.192999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643823 | REC_0009459 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 13.7 | 71 | female | 2 | 18 | 6.8 | 6 | alectinib 600 mg BID | 12.9 | false | MSS | 2026-03-15T05:35:59.193252+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510777 | REC_0009460 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 7.2 | 70 | female | 2 | 12 | 5.3 | 6 | alectinib 600 mg BID | 13.7 | true | MSS | 2026-03-15T05:35:59.193505+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623645 | REC_0009461 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 10.1 | 78 | female | 1 | 18 | 4.6 | 3 | osimertinib 80 mg daily | 14.9 | false | MSI-H | 2026-03-15T05:35:59.193745+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_813989 | REC_0009462 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 18.9 | 74 | female | 1 | 14 | 5.2 | 7 | osimertinib 80 mg daily | 10.7 | false | MSI-H | 2026-03-15T05:35:59.193987+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_742341 | REC_0009463 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 14 | 5.1 | 59 | female | 0 | 14 | 3.5 | 1 | alectinib 600 mg BID | 21.2 | true | MSS | 2026-03-15T05:35:59.194227+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_699428 | REC_0009464 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 13.2 | 57 | female | 0 | 6 | 7 | 4 | entrectinib 600 mg daily | 14.4 | true | MSS | 2026-03-15T05:35:59.194467+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_891934 | REC_0009465 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 19 | 3.5 | 58 | female | 1 | 29 | 5.9 | 2 | pembrolizumab 200 mg q3w | 17.2 | false | MSS | 2026-03-15T05:35:59.194816+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_578403 | REC_0009466 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 5.3 | 57 | male | 0 | 6 | 5.8 | 5 | pembrolizumab 200 mg q3w | 6.9 | false | MSS | 2026-03-15T05:35:59.195071+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_618856 | REC_0009467 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 34 | 10.2 | 75 | female | 3 | 11 | 4.8 | 4 | pembrolizumab 200 mg q3w | 13.7 | false | MSI-H | 2026-03-15T05:35:59.195321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871531 | REC_0009468 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 10.3 | 54 | male | 0 | 19 | 6.4 | 2 | osimertinib 80 mg daily | 13.5 | false | MSI-H | 2026-03-15T05:35:59.195573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947697 | REC_0009469 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 9.4 | 66 | male | 1 | 5 | 3.6 | 2 | osimertinib 80 mg daily | 15.8 | false | MSS | 2026-03-15T05:35:59.195817+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771711 | REC_0009470 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 16.5 | 62 | female | 1 | 3 | 6.1 | 2 | sotorasib 960 mg daily | 18.1 | false | MSS | 2026-03-15T05:35:59.196068+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_389879 | REC_0009471 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 11.2 | 62 | male | 0 | 7 | 4.8 | 9 | osimertinib 80 mg daily | 10.3 | true | MSI-H | 2026-03-15T05:35:59.196522+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_472159 | REC_0009472 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 13 | 11.4 | 67 | female | 0 | 18 | 5.3 | 4 | sotorasib 960 mg daily | 10.8 | false | MSS | 2026-03-15T05:35:59.196783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457778 | REC_0009473 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 9.9 | 67 | female | 0 | 26 | 6.1 | 8 | sotorasib 960 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:59.197032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464628 | REC_0009474 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 12.2 | 54 | female | 0 | 21 | 5 | 7 | sotorasib 960 mg daily | 11 | true | MSI-H | 2026-03-15T05:35:59.197271+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_389311 | REC_0009475 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 11.8 | 66 | male | 0 | 8 | 5 | 1 | osimertinib 80 mg daily | 16.9 | false | MSS | 2026-03-15T05:35:59.197510+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846410 | REC_0009476 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 7 | 76 | female | 0 | 67 | 3.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.6 | false | MSS | 2026-03-15T05:35:59.197741+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_666599 | REC_0009477 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 13.9 | 66 | female | 0 | 13 | 5 | 2 | osimertinib 80 mg daily | 16.2 | false | MSS | 2026-03-15T05:35:59.197978+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584923 | REC_0009478 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 14.1 | 71 | male | 1 | 18 | 5.5 | 1 | pembrolizumab 200 mg q3w | 23.9 | false | MSI-H | 2026-03-15T05:35:59.198341+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864943 | REC_0009479 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 14 | 5 | 66 | female | 1 | 62 | 5.2 | 6 | pembrolizumab 200 mg q3w | 7 | true | MSS | 2026-03-15T05:35:59.198602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256574 | REC_0009480 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 16 | 72 | female | 0 | 13 | 7 | 2 | osimertinib 80 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:59.198848+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257105 | REC_0009481 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 16.6 | 62 | female | 0 | 11 | 6.7 | 5 | osimertinib 80 mg daily | 9.6 | true | MSS | 2026-03-15T05:35:59.199091+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_682494 | REC_0009482 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 15.5 | 74 | female | 2 | 9 | 5.4 | 9 | osimertinib 80 mg daily | 5.8 | true | MSS | 2026-03-15T05:35:59.199343+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_130128 | REC_0009483 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 9.6 | 65 | female | 0 | 18 | 4.5 | 1 | sotorasib 960 mg daily | 12.3 | true | MSS | 2026-03-15T05:35:59.199587+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_431652 | REC_0009484 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 8.9 | 62 | female | 0 | 30 | 6.8 | 6 | osimertinib 80 mg daily | 13.3 | true | MSS | 2026-03-15T05:35:59.199827+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_232574 | REC_0009485 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 29 | 8.4 | 63 | female | 1 | 12 | 4.4 | 1 | pembrolizumab 200 mg q3w | 15.9 | false | MSS | 2026-03-15T05:35:59.200065+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233812 | REC_0009486 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 16.6 | 78 | female | 2 | 12 | 6.2 | 6 | alectinib 600 mg BID | 7.2 | false | MSS | 2026-03-15T05:35:59.200388+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281779 | REC_0009487 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 23 | 7.8 | 68 | male | 1 | 48 | 6.4 | 0 | carboplatin + paclitaxel + pembrolizumab | 30.9 | true | MSS | 2026-03-15T05:35:59.200640+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_856439 | REC_0009488 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 7.8 | 60 | male | 0 | 9 | 6.4 | 1 | entrectinib 600 mg daily | 20 | false | MSS | 2026-03-15T05:35:59.200886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_129302 | REC_0009489 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.6 | 56 | female | 1 | 14 | 5.4 | 5 | osimertinib 80 mg daily | 7.9 | true | MSI-H | 2026-03-15T05:35:59.201135+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_387272 | REC_0009490 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 8.7 | 80 | female | 1 | 20 | 6 | 7 | pembrolizumab 200 mg q3w | 13.7 | false | MSS | 2026-03-15T05:35:59.201376+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_884139 | REC_0009491 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 5.1 | 74 | female | 2 | 22 | 7.2 | 3 | pembrolizumab 200 mg q3w | 16.2 | false | MSS | 2026-03-15T05:35:59.201707+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_549715 | REC_0009492 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 14.9 | 76 | female | 2 | 12 | 7.9 | 2 | entrectinib 600 mg daily | 14.5 | false | MSI-H | 2026-03-15T05:35:59.201957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_318007 | REC_0009493 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 10.5 | 78 | male | 1 | 20 | 4.8 | 6 | entrectinib 600 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:59.202209+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956281 | REC_0009494 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 7.8 | 85 | female | 3 | 8 | 5.7 | 5 | sotorasib 960 mg daily | 6.3 | false | MSS | 2026-03-15T05:35:59.202446+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_331424 | REC_0009495 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 4.8 | 59 | female | 0 | 17 | 5.1 | 7 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:59.202684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_613549 | REC_0009496 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 34 | 8.8 | 62 | female | 0 | 10 | 5.1 | 2 | pembrolizumab 200 mg q3w | 8.5 | true | MSS | 2026-03-15T05:35:59.202922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712426 | REC_0009497 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 15.1 | 69 | female | 1 | 9 | 5.5 | 2 | alectinib 600 mg BID | 16.9 | false | MSI-H | 2026-03-15T05:35:59.203164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224594 | REC_0009498 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 9.5 | 78 | female | 2 | 18 | 6.8 | 1 | osimertinib 80 mg daily | 30.6 | false | MSS | 2026-03-15T05:35:59.203395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_502576 | REC_0009499 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 11.3 | 68 | female | 1 | 19 | 4.6 | 1 | sotorasib 960 mg daily | 20.4 | true | MSI-H | 2026-03-15T05:35:59.203633+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584377 | REC_0009500 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 7.8 | 64 | male | 1 | 9 | 6.6 | 1 | osimertinib 80 mg daily | 17.8 | false | MSS | 2026-03-15T05:35:59.203870+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.